Lindemann Dana M, Carpenter James W, KuKanich Butch
J Avian Med Surg. 2016 Mar;30(1):14-22. doi: 10.1647/2014-065.
To determine the pharmacokinetics of meloxicam in Caribbean flamingos ( Phoenicopterus ruber ruber), a pilot study was performed first, followed by a complete pharmacokinetic study. Four healthy birds were divided into 2 groups and administered 1 mg/kg of either oral (n = 2) or subcutaneous (n = 2) meloxicam. Plasma meloxicam concentrations were determined with liquid chromatography-mass spectrometry. Based on the pilot study results, 12 healthy birds were assigned into 2 groups and administered either 3 mg/kg PO (n = 6) or 1.5 mg/kg SC (n = 6) of meloxicam. Blood samples were collected at baseline and at 9 time intervals per group after administration of meloxicam in all flamingos. Plasma concentrations after administration of 3 mg/kg PO meloxicam reached a mean maximum plasma concentration of 1.449 μg/mL at 2.35 hours with a terminal half-life of 1.832 hours. After administration of 1.5 mg/kg SC meloxicam, maximum plasma concentration was 4.059 μg/mL at 0.91 hour with a terminal half-life of 1.104 hours. The plasma profile from the main oral study (3 mg/kg PO) differed markedly from the pilot study (1 mg/kg PO), suggesting a delayed absorption with the higher dose and lack of dose proportionality. The different doses for subcutaneous administration resulted in a proportional change in plasma concentrations. Further studies are needed to evaluate the effects of the drug volume administered and fasting status when oral dosing is used. Future studies are also needed to investigate multiple-dose pharmacokinetics of meloxicam and to determine the therapeutic meloxicam plasma concentration in Caribbean flamingos.
为了确定美洛昔康在加勒比火烈鸟(Phoenicopterus ruber ruber)体内的药代动力学,首先进行了一项初步研究,随后开展了一项完整的药代动力学研究。将四只健康的鸟类分为两组,分别给予1mg/kg的口服(n = 2)或皮下注射(n = 2)美洛昔康。采用液相色谱 - 质谱法测定血浆中美洛昔康的浓度。根据初步研究结果,将12只健康鸟类分为两组,分别给予3mg/kg口服(n = 6)或1.5mg/kg皮下注射(n = 6)美洛昔康。在所有火烈鸟给药后,于基线及每组9个时间间隔采集血样。给予3mg/kg口服美洛昔康后,血浆浓度在2.35小时达到平均最大血浆浓度1.449μg/mL,终末半衰期为1.832小时。给予1.5mg/kg皮下注射美洛昔康后,最大血浆浓度在0.91小时为4.059μg/mL,终末半衰期为1.104小时。主要口服研究(3mg/kg口服)的血浆曲线与初步研究(1mg/kg口服)明显不同,表明较高剂量时吸收延迟且缺乏剂量比例关系。皮下注射不同剂量导致血浆浓度成比例变化。当采用口服给药时,需要进一步研究以评估给药体积和禁食状态的影响。未来还需要开展研究以调查美洛昔康的多剂量药代动力学,并确定加勒比火烈鸟中美洛昔康的治疗血浆浓度。